Toxicity profile of high‐dose methotrexate in young children with central nervous system tumors-Reference-Cited by-同舟云学术

Toxicity profile of high‐dose methotrexate in young children with central nervous system tumors

Published:2024-07-22 Issue:10 Volume:71 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Chavana Ashley N.¹^ORCID,Taylor Zachary L.²³⁴,DeGroote Nicholas⁵⁶,Lindsay Holly B.⁷⁸^ORCID,Sauer Hannah E.¹⁹^ORCID,Mason Emily J.¹,Schafer Eric S.¹⁹^ORCID,Miller Tamara P.⁵⁶^ORCID,Castellino Sharon M.⁵⁶,Pommert Lauren³⁴^ORCID,O'Brien Maureen M.³⁴,Ramsey Laura B.¹⁰¹¹^ORCID,Bernhardt M. Brooke¹²^ORCID,Brown Austin L.¹⁹^ORCID

Affiliation:

1. Department of Pediatrics Baylor College of Medicine Houston Texas USA

2. Division of Translational and Clinical Pharmacology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA

3. Cancer and Blood Diseases Institute Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA

4. Department of Pediatrics University of Cincinnati College of Medicine Cincinnati Ohio USA

5. Division of Pediatrics Emory University School of Medicine Atlanta Georgia USA

6. Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta Atlanta Georgia USA

7. Center for Cancer and Blood Disorders Children's Hospital Colorado Aurora Colorado USA

8. Department of Pediatrics University of Colorado Anschutz Medical Campus Aurora Colorado USA

9. Texas Children's Cancer and Hematology Center Texas Children's Hospital Houston Texas USA

10. Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation Children's Mercy Kansas City Kansas City Missouri USA

11. Department of Pediatrics School of Medicine University of Missouri Kansas City Kansas City Missouri USA

12. Department of Pharmacy and Pharmaceutical Science St. Jude Children's Research Hospital Memphis Tennessee USA

Abstract

AbstractHigh‐dose methotrexate (HD‐MTX) is used in the treatment of children with central nervous system (CNS) tumors; however, toxicity information is limited. We characterized toxicities following 102 administrations of HD‐MTX (4.6–13.5 g/m2) infused over 4 or 24 h in 38 children with a CNS tumor before 6 years of age (2010–2020). Delayed clearance of methotrexate occurred following 24% of infusions. Common Terminology Criteria for Adverse Events v5 grade 2–3 mucositis was observed in 47% of individuals, Grade 4 neutropenia in 76%, and grade 3–4 thrombocytopenia in 58%. No neurotoxicity was observed. HD‐MTX can be safely used with supportive care and monitoring.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.31213

Reference18 articles.

1. Population pharmacokinetics of methotrexate and 7-hydroxymethotrexate and delayed excretion in infants and young children with brain tumors

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on: Toxicity profile of high‐dose methotrexate in young children with central nervous system tumors;Pediatric Blood & Cancer;2024-08-08